Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Eron, J.J.; Orkin, C.; Cunningham, D.; Pulido, F.; Post, F.A.; De Wit, S.; Lathouwers, E.; Hufkens, V.; Jezorwski, J.; Petrovic, R.; Brown, K.; Van Landuyt, E.; Opsomer, M.; De Wit, S.; Florence, E.; Moutschen, M.; Van Wijngaerden, E.; Vandekerckhove, L.; Vandercam, B.; Brunetta, J.; Conway, B.; Klein, M.; Murphy, D.; Rachlis, A.; Shafran, S.; Walmsley, S.; Ajana, F.; Cotte, L.; Girardy, P.-M.; Katlama, C.; Molina, J.-M.; Poizot-Martin, I.; Raffi, F.; Rey, D.; Reynes, J.; Teicher, E.; Yazdanpanah, Y.; Gasiorowski, J.; Halota, W.; Horban, A.; Piekarska, A.; Witor, A.; Arribas, J.R.; Perez-Valero, I.; Berenguer, J.; Casado, J.; Gatell, J.M.; Gutierrez, F.; Galindo, M.J.; Gutierrez, M.D.M.; Iribarren, J.A.; Knobel, H.; Negredo, E.; Pineda, J.A.; Podzamczer, D.; Sogorb, J.P.; Pulido, F.; Ricart, C.; Rivero, A.; Santos Gil, I.; Blaxhult, A.; Flamholc, L.; Gisslèn, M.; Thalme, A.; Fehr, J.; Rauch, A.; Stoeckle, M.; Clarke, A.; Gazzard, B.G.; Johnson, M.A.; Orkin, C.; Ustianowski, A.; Waters, L.; Bailey, J.; Benson, P.; Bhatti, L.; Brar, I.; Bredeek, U.F.; Brinson, C.; Crofoot, G.; Cunningham, D.; DeJesus, E.; Dietz, C.; Dretler, R.; Eron, J.; Felizarta, F.; Fichtenbaum, C.; Gallant, J.; Gathe, J.; Hagins, D.; Henn, S.; Henry, W.K.; Huhn, G.; Jain, M.; Lucasti, C.; Martorell, C.; McDonald, C.; Mills, A.; Morales-Ramirez, J.; Mounzer, K.; Nahass, R.; Olivet, H.; Osiyemi, O.; Prelutsky, D.; Ramgopal, M.; Rashbaum, B.; Richmond, G.; Ruane, P.; Scarsella, A.; Scribner, A.; Shalit, P.; Shamblaw, D.; Slim, J.; Tashima, K.; Voskuhl, G.; Ward, D.; Wilkin, A.; de Vente, J.

doi:10.1016/J.ANTIVIRAL.2019.104543

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Eron, J.J.
Orkin, C.
Cunningham, D.
Pulido, F.
Post, F.A.
De Wit, S.
Lathouwers, E.
Hufkens, V.
Jezorwski, J.
Petrovic, R.
Brown, K.
Van Landuyt, E.
Opsomer, M.
De Wit, S.
Florence, E.
Moutschen, M.
Van Wijngaerden, E.
Vandekerckhove, L.
Vandercam, B.
Brunetta, J.
Conway, B.
Klein, M.
Murphy, D.
Rachlis, A.
Shafran, S.
Walmsley, S.
Ajana, F.
Cotte, L.
Girardy, P.-M.
Katlama, C.
Molina, J.-M.
Poizot-Martin, I.
Raffi, F.
Rey, D.
Reynes, J.
Teicher, E.
Yazdanpanah, Y.
Gasiorowski, J.
Halota, W.
Horban, A.
Piekarska, A.
Witor, A.
Arribas, J.R.
Perez-Valero, I.
Berenguer, J.
Casado, J.
Gatell, J.M.
Gutierrez, F.
Galindo, M.J.
Gutierrez, M.D.M.
Iribarren, J.A.
Knobel, H.
Negredo, E.
Pineda, J.A.
Podzamczer, D.
Sogorb, J.P.
Pulido, F.
Ricart, C.
Rivero, A.
Santos Gil, I.
Blaxhult, A.
Flamholc, L.
Gisslèn, M.
Thalme, A.
Fehr, J.
Rauch, A.
Stoeckle, M.
Clarke, A.
Gazzard, B.G.
Johnson, M.A.
Orkin, C.
Ustianowski, A.
Waters, L.
Bailey, J.
Benson, P.
Bhatti, L.
Brar, I.
Bredeek, U.F.
Brinson, C.
Crofoot, G.
Cunningham, D.
DeJesus, E.
Dietz, C.
Dretler, R.
Eron, J.
Felizarta, F.
Fichtenbaum, C.
Gallant, J.
Gathe, J.
Hagins, D.
Henn, S.
Henry, W.K.
Huhn, G.
Jain, M.
Lucasti, C.
Martorell, C.
McDonald, C.
Mills, A.
Morales-Ramirez, J.
Mounzer, K.
Nahass, R.
Olivet, H.
Osiyemi, O.
Prelutsky, D.
Ramgopal, M.
Rashbaum, B.
Richmond, G.
Ruane, P.
Scarsella, A.
Scribner, A.
Shalit, P.
Shamblaw, D.
Slim, J.
Tashima, K.
Voskuhl, G.
Ward, D.
Wilkin, A.
de Vente, J.
Montrer des auteurs +

Revue:

Antiviral Research

ISSN: 1872-9096, 0166-3542

Année de publication: 2019

Volumen: 170

Type: Article

DOI: 10.1016/J.ANTIVIRAL.2019.104543 GOOGLE SCHOLAR Accès ouvert editor

La source de données: Scopus